| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
244,360 |
194,888 |
$17.36M |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
122,463 |
104,341 |
$8.23M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
54,372 |
37,991 |
$7.44M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
95,415 |
79,738 |
$5.75M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
75,516 |
64,637 |
$5.01M |
| 80048 |
Basic metabolic panel (calcium, ionized) |
168,391 |
121,389 |
$4.81M |
| 80053 |
Comprehensive metabolic panel |
114,062 |
79,426 |
$4.20M |
| J9271 |
Injection, pembrolizumab, 1 mg |
2,283 |
1,652 |
$3.45M |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
4,928 |
3,915 |
$3.45M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
39,534 |
25,428 |
$3.29M |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
59,814 |
49,299 |
$2.88M |
| 77386 |
|
12,543 |
1,192 |
$2.12M |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
19,035 |
9,935 |
$2.05M |
| 70450 |
Computed tomography, head or brain; without contrast material |
24,696 |
21,754 |
$2.04M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
24,087 |
21,367 |
$1.88M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
28,229 |
17,139 |
$1.83M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
24,993 |
21,524 |
$1.78M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
22,625 |
20,092 |
$1.67M |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
15,135 |
10,083 |
$1.61M |
| J1569 |
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg |
3,433 |
1,001 |
$1.61M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
59,839 |
22,550 |
$1.42M |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
16,786 |
13,047 |
$1.33M |
| Q3014 |
Telehealth originating site facility fee |
32,407 |
27,894 |
$1.30M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
3,101 |
2,552 |
$1.25M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
209,167 |
149,458 |
$1.24M |
| 96415 |
|
10,306 |
7,342 |
$1.21M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
1,543 |
1,075 |
$1.07M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
9,000 |
7,934 |
$986K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
26,388 |
23,405 |
$941K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
4,502 |
3,890 |
$895K |
| Q5103 |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
2,201 |
1,810 |
$852K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
16,688 |
13,733 |
$849K |
| 96367 |
|
10,796 |
7,027 |
$842K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
12,041 |
10,408 |
$837K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
11,930 |
10,707 |
$833K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
13,597 |
11,724 |
$832K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
26,429 |
23,458 |
$828K |
| 85610 |
|
56,934 |
36,675 |
$808K |
| 77412 |
|
6,247 |
840 |
$805K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
7,824 |
7,032 |
$801K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
135,466 |
93,190 |
$774K |
| 36512 |
|
1,811 |
1,516 |
$738K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
9,442 |
8,056 |
$711K |
| 52000 |
|
2,444 |
2,228 |
$705K |
| 36430 |
|
6,520 |
3,564 |
$694K |
| G0378 |
Hospital observation service, per hour |
26,680 |
22,081 |
$690K |
| J9299 |
Injection, nivolumab, 1 mg |
930 |
535 |
$674K |
| J1459 |
Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg |
1,622 |
638 |
$660K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
3,645 |
3,221 |
$615K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
7,001 |
6,193 |
$610K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
2,549 |
2,243 |
$584K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
8,994 |
7,956 |
$575K |
| 99215 |
Prolong outpt/office vis |
8,765 |
7,696 |
$566K |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
520 |
455 |
$518K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
2,738 |
2,357 |
$514K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
5,056 |
4,545 |
$497K |
| J0475 |
Injection, baclofen, 10 mg |
2,257 |
2,148 |
$494K |
| 64643 |
|
3,810 |
3,507 |
$461K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
11,645 |
9,517 |
$451K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
24,561 |
10,231 |
$439K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
19,376 |
17,423 |
$422K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
11,104 |
6,239 |
$409K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
4,290 |
3,837 |
$405K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
65,697 |
40,343 |
$403K |
| 85027 |
|
81,460 |
60,234 |
$399K |
| 80076 |
|
36,064 |
30,151 |
$398K |
| C9257 |
Injection, bevacizumab, 0.25 mg |
2,497 |
2,192 |
$392K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
5,245 |
4,717 |
$391K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
21,660 |
7,833 |
$386K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
10,815 |
9,766 |
$382K |
| 84484 |
|
54,552 |
27,118 |
$382K |
| 80081 |
|
3,596 |
3,144 |
$376K |
| 87077 |
|
18,571 |
16,051 |
$367K |
| 82962 |
|
14,108 |
12,187 |
$365K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
18,795 |
16,843 |
$362K |
| 93308 |
|
2,969 |
2,574 |
$359K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
1,567 |
1,477 |
$347K |
| 96910 |
|
6,125 |
1,239 |
$336K |
| 64615 |
|
3,712 |
3,383 |
$328K |
| 83735 |
|
78,295 |
46,727 |
$325K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
35,760 |
31,957 |
$323K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
5,988 |
5,452 |
$320K |
| 49083 |
|
2,063 |
949 |
$317K |
| 77336 |
|
5,921 |
2,644 |
$310K |
| J0741 |
Injection, cabotegravir and rilpivirine, 2mg/3mg |
274 |
248 |
$310K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
31,204 |
27,039 |
$309K |
| 83021 |
|
11,022 |
7,361 |
$306K |
| 84443 |
Thyroid stimulating hormone (TSH) |
27,351 |
24,084 |
$305K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
717 |
515 |
$303K |
| 96417 |
|
5,808 |
3,419 |
$299K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
7,281 |
6,484 |
$297K |
| 20610 |
|
5,137 |
4,196 |
$295K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
4,393 |
3,939 |
$294K |
| 74183 |
|
3,040 |
2,672 |
$292K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
9,924 |
4,282 |
$277K |
| 83880 |
|
13,227 |
11,133 |
$273K |
| 95874 |
|
7,214 |
6,610 |
$273K |
| 81025 |
|
20,197 |
17,470 |
$268K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
3,919 |
3,538 |
$267K |
| 80061 |
Lipid panel |
18,218 |
16,266 |
$266K |
| 76830 |
Ultrasound, transvaginal |
6,164 |
5,563 |
$266K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
4,957 |
4,430 |
$255K |
| 87536 |
|
4,210 |
3,572 |
$252K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
6,744 |
5,576 |
$251K |
| 97162 |
|
9,311 |
7,871 |
$248K |
| J2357 |
Injection, omalizumab, 5 mg |
2,357 |
847 |
$244K |
| 95806 |
|
2,077 |
1,968 |
$244K |
| 70496 |
|
2,563 |
2,286 |
$244K |
| 76642 |
|
6,006 |
4,992 |
$238K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
10,550 |
5,204 |
$236K |
| 64644 |
|
3,930 |
3,642 |
$236K |
| 81001 |
|
64,716 |
55,439 |
$235K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
1,327 |
1,138 |
$233K |
| 51705 |
|
3,488 |
2,849 |
$232K |
| J0485 |
Injection, belatacept, 1 mg |
3,293 |
1,498 |
$232K |
| J9312 |
Injection, rituximab, 10 mg |
303 |
172 |
$230K |
| 84702 |
|
9,561 |
7,491 |
$229K |
| 82728 |
|
19,454 |
16,389 |
$225K |
| 83970 |
|
8,897 |
7,679 |
$220K |
| 72131 |
|
6,070 |
5,484 |
$218K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
2,890 |
2,475 |
$209K |
| 95811 |
|
1,025 |
950 |
$207K |
| 67028 |
Intravitreal injection of a pharmacologic agent |
4,191 |
3,662 |
$206K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
5,987 |
5,001 |
$205K |
| 43235 |
|
1,032 |
914 |
$201K |
| 95886 |
|
2,895 |
2,687 |
$200K |
| 76801 |
|
6,776 |
5,892 |
$195K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,794 |
2,473 |
$193K |
| 93971 |
|
6,025 |
5,364 |
$193K |
| 70498 |
|
2,396 |
2,133 |
$191K |
| 36561 |
|
433 |
382 |
$191K |
| 72141 |
|
2,811 |
2,545 |
$190K |
| 70486 |
|
4,664 |
4,234 |
$188K |
| 71250 |
|
5,118 |
4,560 |
$183K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
12,185 |
10,230 |
$181K |
| 87210 |
|
13,725 |
12,278 |
$181K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
7,118 |
6,153 |
$180K |
| 96368 |
|
3,356 |
1,899 |
$179K |
| 90686 |
|
10,357 |
9,431 |
$177K |
| 64616 |
|
1,909 |
1,734 |
$175K |
| 76770 |
|
3,106 |
2,867 |
$175K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
3,507 |
3,200 |
$170K |
| 72128 |
|
4,725 |
4,262 |
$170K |
| Q5115 |
Injection, rituximab-abbs, biosimilar, (truxima), 10 mg |
203 |
76 |
$169K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
5,714 |
5,270 |
$168K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
5,480 |
4,886 |
$164K |
| 93017 |
|
4,023 |
3,568 |
$163K |
| 72197 |
|
1,543 |
1,333 |
$163K |
| 86480 |
|
3,357 |
2,915 |
$161K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
947 |
758 |
$160K |
| 83690 |
|
28,918 |
23,915 |
$157K |
| J1930 |
Injection, lanreotide, 1 mg |
209 |
190 |
$152K |
| 70491 |
|
2,079 |
1,879 |
$151K |
| 94660 |
|
2,535 |
1,283 |
$147K |
| 82565 |
|
10,051 |
8,324 |
$145K |
| 82805 |
|
6,571 |
5,391 |
$145K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
2,254 |
2,104 |
$143K |
| 71046 |
Radiologic examination, chest; 2 views |
45,418 |
38,901 |
$142K |
| 84100 |
|
54,235 |
31,330 |
$142K |
| 97116 |
|
9,508 |
4,146 |
$139K |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
274 |
158 |
$139K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
1,369 |
1,040 |
$137K |
| 17250 |
|
1,708 |
1,325 |
$137K |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
356 |
145 |
$136K |
| 82607 |
|
10,515 |
9,409 |
$136K |
| 64642 |
|
2,318 |
2,100 |
$135K |
| 84439 |
|
14,080 |
12,185 |
$134K |
| J0178 |
Injection, aflibercept, 1 mg |
1,117 |
998 |
$128K |
| 76813 |
|
3,637 |
3,262 |
$127K |
| 72156 |
|
1,137 |
1,034 |
$127K |
| 86832 |
|
1,892 |
1,533 |
$126K |
| 31575 |
|
2,478 |
2,187 |
$126K |
| 77301 |
|
595 |
509 |
$126K |
| 93296 |
|
4,001 |
3,761 |
$126K |
| 77290 |
|
1,245 |
768 |
$124K |
| 00731 |
|
3,190 |
2,733 |
$124K |
| 93451 |
|
226 |
186 |
$124K |
| 96416 |
|
950 |
588 |
$123K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
10,339 |
8,875 |
$123K |
| 38222 |
|
702 |
463 |
$123K |
| 90715 |
|
9,969 |
9,083 |
$122K |
| 87070 |
|
7,178 |
5,728 |
$119K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
3,918 |
1,329 |
$118K |
| 73221 |
|
1,830 |
1,618 |
$118K |
| 84132 |
|
8,972 |
7,274 |
$117K |
| 80197 |
|
11,406 |
6,517 |
$115K |
| 97163 |
|
5,612 |
4,415 |
$114K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
83,347 |
66,862 |
$113K |
| 80050 |
General health panel |
6,358 |
5,480 |
$112K |
| 77300 |
|
2,044 |
1,438 |
$111K |
| 83615 |
|
29,544 |
16,009 |
$111K |
| 10060 |
|
1,393 |
1,207 |
$111K |
| 93356 |
|
1,126 |
1,003 |
$110K |
| 82784 |
|
7,763 |
6,388 |
$108K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
1,927 |
1,770 |
$108K |
| 94010 |
|
7,934 |
6,744 |
$108K |
| 86803 |
|
9,493 |
8,294 |
$108K |
| C8930 |
Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision |
1,020 |
927 |
$107K |
| 86850 |
|
16,857 |
13,122 |
$106K |
| 93976 |
|
2,341 |
2,124 |
$106K |
| 76536 |
|
2,446 |
2,242 |
$106K |
| 97161 |
|
3,001 |
2,631 |
$105K |
| 87088 |
|
17,054 |
15,110 |
$105K |
| 62370 |
|
2,154 |
2,055 |
$105K |
| 86900 |
|
20,510 |
16,155 |
$104K |
| 83605 |
|
11,407 |
9,268 |
$102K |
| 82105 |
|
5,747 |
4,945 |
$101K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,652 |
2,384 |
$101K |
| 87081 |
|
6,268 |
5,676 |
$101K |
| 93321 |
|
942 |
787 |
$100K |
| J1453 |
Injection, fosaprepitant, 1 mg |
3,690 |
2,372 |
$99K |
| 86833 |
|
1,833 |
1,487 |
$98K |
| 97166 |
|
4,169 |
3,356 |
$98K |
| 19083 |
|
360 |
296 |
$98K |
| Q5106 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units |
2,637 |
1,563 |
$98K |
| 77080 |
|
1,656 |
1,541 |
$96K |
| 64645 |
|
989 |
922 |
$96K |
| 77334 |
|
2,290 |
1,695 |
$96K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
67,453 |
54,237 |
$96K |
| 77066 |
Tomosynthesis, mammo |
3,887 |
3,458 |
$95K |
| 86140 |
|
15,562 |
13,167 |
$95K |
| 87497 |
|
3,750 |
2,294 |
$93K |
| 82570 |
|
12,219 |
9,957 |
$92K |
| 87186 |
|
13,590 |
11,695 |
$91K |
| 97165 |
|
2,985 |
2,514 |
$91K |
| 77065 |
Tomosynthesis, mammo |
4,378 |
3,596 |
$91K |
| 36902 |
|
270 |
224 |
$90K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
4,486 |
4,128 |
$90K |
| 93798 |
|
2,062 |
402 |
$90K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
1,253 |
1,060 |
$88K |
| 86923 |
|
7,365 |
4,184 |
$86K |
| 86592 |
|
10,731 |
9,443 |
$86K |
| 86902 |
|
3,027 |
2,372 |
$86K |
| 94060 |
|
3,694 |
3,355 |
$85K |
| 76882 |
|
2,010 |
1,822 |
$84K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
1,593 |
962 |
$84K |
| 72158 |
|
964 |
869 |
$82K |
| 93970 |
|
1,787 |
1,615 |
$82K |
| 93922 |
|
3,647 |
3,315 |
$82K |
| 76512 |
|
2,062 |
1,716 |
$82K |
| 97535 |
Self-care/home management training, each 15 minutes |
7,332 |
3,605 |
$81K |
| 12002 |
|
992 |
915 |
$81K |
| J0588 |
Injection, incobotulinumtoxin a, 1 unit |
668 |
467 |
$81K |
| 84550 |
|
29,346 |
16,396 |
$80K |
| 31579 |
|
553 |
515 |
$80K |
| 74174 |
|
1,109 |
977 |
$79K |
| 12001 |
|
971 |
882 |
$79K |
| 20611 |
|
693 |
592 |
$78K |
| 83550 |
|
14,751 |
13,055 |
$77K |
| 82950 |
|
3,915 |
3,595 |
$76K |
| 82746 |
|
7,596 |
6,841 |
$76K |
| 74160 |
|
1,140 |
1,031 |
$76K |
| 82947 |
|
4,375 |
3,616 |
$75K |
| 83540 |
|
17,220 |
15,283 |
$74K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
3,216 |
1,863 |
$72K |
| 31231 |
|
1,203 |
1,072 |
$72K |
| 72157 |
|
712 |
646 |
$70K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
12,487 |
11,200 |
$67K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
1,386 |
1,246 |
$67K |
| 91322 |
|
1,159 |
983 |
$67K |
| J0586 |
Injection, abobotulinumtoxina, 5 units |
706 |
485 |
$66K |
| G0008 |
Administration of influenza virus vaccine |
14,409 |
12,956 |
$65K |
| 43762 |
|
956 |
845 |
$65K |
| 84153 |
|
4,327 |
3,564 |
$64K |
| 82533 |
|
3,801 |
2,829 |
$64K |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
291 |
119 |
$64K |
| 74230 |
|
1,076 |
961 |
$64K |
| J2323 |
Injection, natalizumab, 1 mg |
83 |
74 |
$64K |
| J2350 |
Injection, ocrelizumab, 1 mg |
13 |
12 |
$62K |
| 82024 |
|
1,951 |
1,679 |
$62K |
| 84403 |
|
3,272 |
2,883 |
$62K |
| 86360 |
|
1,824 |
1,569 |
$61K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
810 |
370 |
$61K |
| Q0222 |
Injection, bebtelovimab, 175 mg |
68 |
54 |
$59K |
| 29581 |
|
722 |
203 |
$59K |
| 87040 |
|
8,992 |
3,675 |
$58K |
| 87522 |
Neg quan hep c or qual rna |
1,599 |
1,412 |
$58K |
| 92557 |
|
2,772 |
2,512 |
$58K |
| 82670 |
|
2,161 |
1,882 |
$57K |
| J1756 |
Injection, iron sucrose, 1 mg |
5,446 |
2,776 |
$57K |
| 86160 |
|
3,222 |
2,800 |
$56K |
| 86334 |
|
5,594 |
4,560 |
$55K |
| 74018 |
|
7,263 |
6,274 |
$55K |
| 80177 |
|
3,354 |
2,951 |
$55K |
| 82043 |
|
4,990 |
4,508 |
$54K |
| 86359 |
|
1,892 |
1,612 |
$54K |
| 01922 |
|
703 |
574 |
$53K |
| 85379 |
|
7,034 |
5,983 |
$53K |
| 73700 |
|
1,205 |
1,047 |
$52K |
| 87799 |
|
2,492 |
1,686 |
$51K |
| 64612 |
|
672 |
611 |
$51K |
| J9310 |
Injection, rituximab, 100 mg |
70 |
52 |
$51K |
| 82378 |
|
4,227 |
3,371 |
$51K |
| 77001 |
|
2,308 |
1,970 |
$50K |
| 77062 |
|
2,927 |
2,661 |
$50K |
| 77061 |
|
2,995 |
2,511 |
$49K |
| 82330 |
|
3,546 |
2,540 |
$49K |
| 85730 |
|
13,538 |
11,561 |
$49K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
286 |
243 |
$49K |
| 97167 |
|
3,117 |
2,307 |
$48K |
| 82550 |
|
6,910 |
5,408 |
$48K |
| J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units |
1,056 |
692 |
$48K |
| 52287 |
|
262 |
239 |
$46K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,725 |
2,491 |
$46K |
| 92134 |
|
13,849 |
12,217 |
$46K |
| 82375 |
|
2,655 |
2,214 |
$45K |
| 47562 |
|
28 |
26 |
$44K |
| J0897 |
Injection, denosumab, 1 mg |
433 |
390 |
$44K |
| 82077 |
|
4,376 |
3,732 |
$44K |
| 92002 |
|
729 |
658 |
$44K |
| 73030 |
|
11,185 |
9,503 |
$43K |
| 73560 |
|
13,784 |
11,571 |
$43K |
| 11900 |
|
697 |
616 |
$43K |
| 77002 |
|
959 |
881 |
$43K |
| 86706 |
|
6,353 |
5,421 |
$41K |
| 80164 |
|
2,126 |
1,788 |
$41K |
| 83516 |
|
3,952 |
2,925 |
$41K |
| 87340 |
|
6,938 |
5,908 |
$41K |
| 93325 |
|
1,517 |
1,281 |
$41K |
| 51702 |
|
3,014 |
2,495 |
$40K |
| 12011 |
|
580 |
521 |
$40K |
| 80069 |
|
1,524 |
1,343 |
$40K |
| 77295 |
|
202 |
157 |
$40K |
| 80143 |
|
3,094 |
2,673 |
$40K |
| 86039 |
|
4,085 |
3,560 |
$39K |
| 97597 |
|
796 |
599 |
$39K |
| 87450 |
|
3,801 |
3,466 |
$38K |
| 92083 |
|
7,234 |
6,513 |
$38K |
| 92611 |
|
942 |
769 |
$38K |
| 70543 |
|
338 |
311 |
$37K |
| 73630 |
|
10,880 |
9,031 |
$36K |
| 84146 |
|
2,277 |
2,019 |
$36K |
| J1610 |
Injection, glucagon hydrochloride, per 1 mg |
1,185 |
992 |
$35K |
| 80175 |
|
1,687 |
1,462 |
$35K |
| 87493 |
|
1,327 |
1,159 |
$35K |
| 88307 |
|
5,267 |
3,028 |
$35K |
| 82150 |
|
4,037 |
2,936 |
$35K |
| 87632 |
|
261 |
222 |
$34K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
99 |
92 |
$34K |
| 11104 |
|
303 |
271 |
$34K |
| 88264 |
|
537 |
382 |
$34K |
| 83001 |
|
2,217 |
1,967 |
$34K |
| J0791 |
Injection, crizanlizumab-tmca, 5 mg |
112 |
80 |
$33K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
141 |
128 |
$33K |
| 87641 |
|
836 |
742 |
$33K |
| 36821 |
|
57 |
40 |
$33K |
| J9035 |
Injection, bevacizumab, 10 mg |
48 |
26 |
$33K |
| G0257 |
Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility |
1,489 |
958 |
$33K |
| 86301 |
|
2,952 |
2,343 |
$33K |
| 72100 |
|
4,905 |
4,491 |
$33K |
| 84703 |
|
2,712 |
2,291 |
$33K |
| 83883 |
|
3,421 |
2,801 |
$33K |
| 58661 |
|
35 |
27 |
$32K |
| J2353 |
Injection, octreotide, depot form for intramuscular injection, 1 mg |
57 |
53 |
$32K |
| 81003 |
|
6,986 |
6,196 |
$32K |
| 86304 |
|
2,313 |
1,745 |
$32K |
| 70544 |
|
294 |
265 |
$32K |
| 80179 |
|
2,948 |
2,564 |
$32K |
| 58300 |
|
646 |
538 |
$32K |
| 76942 |
|
3,251 |
2,667 |
$31K |
| 86235 |
|
408 |
336 |
$31K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
102 |
85 |
$31K |
| 84156 |
|
12,270 |
9,935 |
$31K |
| 00811 |
|
1,265 |
1,098 |
$30K |
| 83010 |
|
3,174 |
2,353 |
$30K |
| 92235 |
|
563 |
504 |
$30K |
| 73610 |
|
11,540 |
9,673 |
$30K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
1,066 |
929 |
$30K |
| 76937 |
|
3,331 |
2,754 |
$30K |
| 59025 |
Fetal non-stress test |
284 |
187 |
$29K |
| 86704 |
|
3,149 |
2,719 |
$29K |
| 11100 |
|
250 |
218 |
$29K |
| 86901 |
|
15,700 |
12,340 |
$29K |
| 84165 |
|
5,837 |
4,775 |
$29K |
| 85097 |
|
951 |
621 |
$29K |
| 93880 |
|
1,206 |
1,105 |
$29K |
| 88275 |
|
772 |
560 |
$28K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
524 |
340 |
$28K |
| 82040 |
|
2,191 |
1,933 |
$28K |
| 73502 |
|
7,394 |
6,543 |
$28K |
| 58100 |
|
265 |
221 |
$28K |
| 91010 |
|
199 |
183 |
$27K |
| 51728 |
|
250 |
230 |
$27K |
| 86225 |
|
2,838 |
2,475 |
$27K |
| 72040 |
|
1,807 |
1,592 |
$27K |
| 84425 |
|
1,869 |
1,699 |
$26K |
| 82248 |
|
5,542 |
4,071 |
$26K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
1,548 |
1,207 |
$26K |
| 00813 |
|
796 |
682 |
$26K |
| 93225 |
|
1,322 |
1,203 |
$26K |
| 77470 |
|
252 |
208 |
$26K |
| 84630 |
|
3,594 |
3,296 |
$26K |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
113 |
64 |
$25K |
| J0875 |
Injection, dalbavancin, 5 mg |
36 |
24 |
$25K |
| 81002 |
|
1,146 |
851 |
$25K |
| 84145 |
|
1,813 |
1,511 |
$25K |
| 77338 |
|
518 |
481 |
$25K |
| 43760 |
|
207 |
177 |
$24K |
| 85018 |
|
6,419 |
5,171 |
$24K |
| 93320 |
|
228 |
199 |
$24K |
| 84481 |
|
2,194 |
1,909 |
$24K |
| 76519 |
|
601 |
536 |
$23K |
| 76870 |
|
658 |
597 |
$23K |
| 85049 |
|
1,647 |
1,440 |
$23K |
| 36592 |
|
13,178 |
7,416 |
$23K |
| 36591 |
|
18,118 |
10,540 |
$23K |
| 64400 |
|
174 |
161 |
$23K |
| 90670 |
|
988 |
885 |
$23K |
| P9047 |
Infusion, albumin (human), 25%, 50 ml |
204 |
89 |
$22K |
| 17110 |
|
376 |
338 |
$22K |
| 11102 |
|
227 |
204 |
$21K |
| 94726 |
|
3,463 |
3,035 |
$21K |
| 86708 |
|
2,195 |
1,894 |
$21K |
| 71045 |
Radiologic examination, chest; single view |
29,405 |
25,151 |
$21K |
| 94770 |
|
409 |
243 |
$21K |
| 88112 |
|
2,297 |
1,950 |
$21K |
| G0422 |
Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session |
1,028 |
177 |
$21K |
| 92133 |
|
8,291 |
7,544 |
$20K |
| J3471 |
Injection, hyaluronidase, ovine, preservative free, per 1 usp unit (up to 999 usp units) |
1,528 |
1,207 |
$20K |
| 76000 |
|
2,308 |
1,810 |
$20K |
| 87075 |
|
3,216 |
2,567 |
$20K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
55,529 |
39,798 |
$20K |
| 73130 |
|
8,261 |
6,592 |
$20K |
| 83521 |
|
1,591 |
1,220 |
$20K |
| 84466 |
|
2,267 |
2,095 |
$20K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
1,276 |
1,155 |
$20K |
| 96900 |
|
1,165 |
257 |
$20K |
| 86705 |
|
2,406 |
2,039 |
$20K |
| 36415 |
Collection of venous blood by venipuncture |
95,386 |
67,546 |
$19K |
| 00400 |
|
326 |
237 |
$19K |
| 85045 |
|
7,886 |
5,934 |
$19K |
| 88271 |
|
732 |
541 |
$19K |
| 82140 |
|
882 |
742 |
$19K |
| 72146 |
|
282 |
258 |
$18K |
| 78431 |
|
61 |
54 |
$18K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
33,754 |
16,748 |
$18K |
| 88237 |
|
572 |
412 |
$18K |
| 76820 |
|
1,562 |
632 |
$18K |
| 85652 |
|
10,505 |
9,085 |
$18K |
| 90480 |
|
1,189 |
1,007 |
$18K |
| 84450 |
|
3,752 |
3,147 |
$18K |
| 64646 |
|
391 |
349 |
$18K |
| 87205 |
|
6,450 |
5,227 |
$17K |
| 85014 |
|
3,479 |
2,872 |
$17K |
| 82948 |
|
550 |
468 |
$17K |
| 87529 |
|
288 |
256 |
$17K |
| 84460 |
|
3,564 |
2,876 |
$17K |
| 97542 |
|
1,646 |
1,264 |
$17K |
| 83002 |
|
1,259 |
1,140 |
$17K |
| 87102 |
|
2,157 |
1,726 |
$16K |
| 92523 |
|
479 |
362 |
$16K |
| 96523 |
|
541 |
454 |
$16K |
| 87430 |
|
621 |
562 |
$16K |
| 92020 |
|
1,036 |
925 |
$16K |
| 96402 |
|
2,269 |
1,892 |
$15K |
| 75561 |
|
157 |
131 |
$15K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
1,175 |
1,036 |
$15K |
| 84305 |
|
1,085 |
979 |
$15K |
| 95885 |
|
236 |
215 |
$15K |
| Q5122 |
Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg |
14 |
12 |
$15K |
| 87640 |
|
299 |
267 |
$14K |
| 51741 |
|
354 |
323 |
$14K |
| 93926 |
|
873 |
778 |
$14K |
| G0009 |
Administration of pneumococcal vaccine |
3,875 |
3,408 |
$14K |
| 87015 |
|
861 |
649 |
$14K |
| J9070 |
Cyclophosphamide, 100 mg |
560 |
237 |
$14K |
| Q5111 |
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
39 |
28 |
$14K |
| 94762 |
|
445 |
400 |
$14K |
| 83921 |
|
887 |
812 |
$13K |
| 72050 |
|
1,041 |
953 |
$13K |
| 86316 |
|
1,043 |
898 |
$13K |
| 88184 |
|
2,388 |
1,768 |
$13K |
| 86922 |
|
2,028 |
613 |
$13K |
| 90732 |
|
1,538 |
1,384 |
$13K |
| 87206 |
|
2,735 |
2,112 |
$13K |
| 87808 |
|
954 |
865 |
$12K |
| 73110 |
|
5,230 |
4,268 |
$12K |
| 86361 |
|
580 |
500 |
$12K |
| 73562 |
|
3,414 |
3,017 |
$12K |
| 94618 |
|
1,706 |
1,501 |
$12K |
| 73552 |
|
5,384 |
4,792 |
$12K |
| 20605 |
|
146 |
130 |
$12K |
| 74019 |
|
1,660 |
1,508 |
$12K |
| 90662 |
|
2,946 |
2,508 |
$11K |
| 92610 |
|
592 |
455 |
$11K |
| 36000 |
|
10,308 |
9,134 |
$11K |
| 86644 |
|
1,072 |
793 |
$11K |
| 51798 |
|
5,651 |
5,016 |
$11K |
| P9045 |
Infusion, albumin (human), 5%, 250 ml |
237 |
96 |
$11K |
| 20680 |
|
16 |
12 |
$11K |
| 36832 |
|
14 |
12 |
$11K |
| 83520 |
|
750 |
660 |
$11K |
| 94729 |
|
4,699 |
4,164 |
$11K |
| 10005 |
|
59 |
49 |
$11K |
| M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
74 |
57 |
$11K |
| 00790 |
|
113 |
93 |
$11K |
| 93270 |
|
575 |
518 |
$11K |
| 95816 |
|
83 |
76 |
$10K |
| 00840 |
|
148 |
115 |
$10K |
| 88280 |
|
706 |
511 |
$10K |
| 92250 |
|
5,175 |
4,529 |
$10K |
| 73590 |
|
6,349 |
5,356 |
$10K |
| 96401 |
|
1,515 |
739 |
$10K |
| 90651 |
|
239 |
215 |
$10K |
| 88185 |
|
2,233 |
1,640 |
$10K |
| 78306 |
|
129 |
119 |
$10K |
| 92567 |
|
1,042 |
936 |
$10K |
| 90677 |
|
1,055 |
895 |
$9K |
| 80165 |
|
899 |
794 |
$9K |
| 86800 |
|
838 |
714 |
$9K |
| 0124A |
|
762 |
623 |
$9K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
50 |
42 |
$9K |
| 72072 |
|
1,508 |
1,370 |
$9K |
| 85651 |
|
3,776 |
3,207 |
$9K |
| 0399T |
|
303 |
255 |
$9K |
| 67228 |
|
47 |
41 |
$9K |
| 73080 |
|
3,660 |
3,147 |
$8K |
| 89051 |
|
1,323 |
1,000 |
$8K |
| 45300 |
|
43 |
36 |
$8K |
| 0003A |
|
424 |
361 |
$8K |
| 86780 |
|
918 |
822 |
$8K |
| 75574 |
|
78 |
66 |
$8K |
| 76498 |
|
181 |
129 |
$8K |
| 82010 |
|
1,191 |
1,007 |
$8K |
| 85007 |
|
5,216 |
3,173 |
$8K |
| 73564 |
|
1,841 |
1,643 |
$8K |
| 90791 |
Psychiatric diagnostic evaluation |
216 |
183 |
$8K |
| 01844 |
|
90 |
84 |
$8K |
| 82103 |
|
664 |
599 |
$8K |
| 86769 |
|
270 |
237 |
$8K |
| 80235 |
|
407 |
360 |
$8K |
| 58301 |
|
147 |
129 |
$7K |
| 43249 |
|
31 |
26 |
$7K |
| 87517 |
|
269 |
228 |
$7K |
| 82088 |
|
247 |
193 |
$7K |
| 90656 |
|
963 |
893 |
$7K |
| 96409 |
|
1,700 |
750 |
$7K |
| 82310 |
|
940 |
761 |
$7K |
| 80051 |
|
274 |
220 |
$7K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
16,455 |
6,014 |
$7K |
| 20553 |
|
132 |
110 |
$7K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
226 |
171 |
$6K |
| 87521 |
Neg quan hep c or qual rna |
273 |
248 |
$6K |
| 51797 |
|
612 |
566 |
$6K |
| 87902 |
|
26 |
25 |
$6K |
| 95911 |
|
143 |
133 |
$6K |
| 74178 |
|
95 |
86 |
$6K |
| 01480 |
|
104 |
81 |
$6K |
| 29405 |
|
77 |
64 |
$6K |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
2,055 |
1,622 |
$6K |
| 73521 |
|
779 |
717 |
$6K |
| 82610 |
|
656 |
562 |
$6K |
| 82747 |
|
532 |
495 |
$6K |
| 0001A |
|
225 |
198 |
$6K |
| J3489 |
Injection, zoledronic acid, 1 mg |
1,212 |
1,081 |
$6K |
| 86431 |
|
1,521 |
1,334 |
$6K |
| C1776 |
Joint device (implantable) |
197 |
174 |
$6K |
| 0002A |
|
220 |
203 |
$6K |
| 82977 |
|
1,005 |
766 |
$6K |
| 93750 |
|
339 |
241 |
$6K |
| 93242 |
|
294 |
271 |
$6K |
| 94799 |
|
5,885 |
3,780 |
$6K |
| 88342 |
|
3,873 |
3,035 |
$6K |
| J9041 |
Injection, bortezomib, 0.1 mg |
50 |
12 |
$6K |
| 88360 |
|
524 |
412 |
$6K |
| 87106 |
|
827 |
698 |
$5K |
| 86355 |
|
206 |
184 |
$5K |
| 92504 |
|
667 |
573 |
$5K |
| 87045 |
|
418 |
342 |
$5K |
| P9037 |
Platelets, pheresis, leukocytes reduced, irradiated, each unit |
27 |
13 |
$5K |
| 82785 |
|
292 |
259 |
$5K |
| 86665 |
|
375 |
290 |
$5K |
| 73090 |
|
2,964 |
2,538 |
$5K |
| 71271 |
|
111 |
94 |
$5K |
| 93975 |
|
110 |
101 |
$5K |
| 95819 |
|
39 |
36 |
$5K |
| 88341 |
|
1,172 |
964 |
$5K |
| 96376 |
|
24,896 |
15,602 |
$5K |
| 86787 |
|
839 |
697 |
$5K |
| 36589 |
|
30 |
28 |
$5K |
| 83050 |
|
2,213 |
1,831 |
$5K |
| 86255 |
|
618 |
518 |
$5K |
| 70546 |
|
52 |
50 |
$5K |
| 90739 |
|
566 |
503 |
$5K |
| 94667 |
|
320 |
282 |
$4K |
| 00142 |
|
112 |
90 |
$4K |
| 11721 |
|
274 |
244 |
$4K |
| 72170 |
|
2,339 |
2,077 |
$4K |
| 86880 |
|
1,209 |
935 |
$4K |
| 93990 |
|
751 |
600 |
$4K |
| 92136 |
|
943 |
870 |
$4K |
| 89050 |
|
769 |
625 |
$4K |
| 72190 |
|
1,762 |
1,548 |
$4K |
| 88172 |
|
708 |
591 |
$4K |
| 87116 |
|
676 |
516 |
$4K |
| 82951 |
|
85 |
84 |
$4K |
| 36558 |
|
17 |
12 |
$4K |
| 74170 |
|
87 |
80 |
$4K |
| G0423 |
Intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session |
540 |
108 |
$4K |
| 86762 |
|
321 |
292 |
$4K |
| L2112 |
Ankle foot orthosis, fracture orthosis, tibial fracture orthosis, soft, prefabricated, includes fitting and adjustment |
329 |
301 |
$4K |
| 86147 |
|
260 |
214 |
$4K |
| 86870 |
|
247 |
177 |
$4K |
| 95970 |
|
146 |
136 |
$4K |
| 64999 |
|
43 |
13 |
$4K |
| 95909 |
|
57 |
52 |
$4K |
| 85520 |
|
76 |
51 |
$4K |
| 84432 |
|
291 |
245 |
$4K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
55,531 |
44,145 |
$4K |
| 36593 |
|
381 |
305 |
$4K |
| G0010 |
Administration of hepatitis b vaccine |
1,020 |
914 |
$4K |
| 80158 |
|
114 |
62 |
$4K |
| 95912 |
|
112 |
96 |
$4K |
| 73140 |
|
1,330 |
1,107 |
$3K |
| P9073 |
Platelets, pheresis, pathogen-reduced, each unit |
30 |
12 |
$3K |
| 00140 |
|
69 |
65 |
$3K |
| 82104 |
|
360 |
322 |
$3K |
| 80185 |
|
258 |
218 |
$3K |
| L2114 |
Ankle foot orthosis, fracture orthosis, tibial fracture orthosis, semi-rigid, prefabricated, includes fitting and adjustment |
442 |
394 |
$3K |
| 90740 |
|
75 |
71 |
$3K |
| J1442 |
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram |
48 |
14 |
$3K |
| M0239 |
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring |
15 |
13 |
$3K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
55 |
50 |
$3K |
| 80201 |
|
263 |
241 |
$3K |
| 86357 |
|
123 |
114 |
$3K |
| 82542 |
|
161 |
138 |
$3K |
| 11982 |
|
17 |
12 |
$3K |
| 73060 |
|
2,731 |
2,262 |
$3K |
| 83519 |
|
145 |
118 |
$3K |
| 91120 |
|
58 |
51 |
$3K |
| 86200 |
|
369 |
333 |
$3K |
| 19081 |
|
15 |
13 |
$3K |
| 78816 |
|
12 |
12 |
$3K |
| 87563 |
|
132 |
118 |
$3K |
| 84244 |
|
186 |
151 |
$3K |
| 97802 |
|
63 |
52 |
$3K |
| 84134 |
|
327 |
280 |
$3K |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
93 |
88 |
$3K |
| 87181 |
|
135 |
113 |
$3K |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
12 |
12 |
$3K |
| 87631 |
|
60 |
48 |
$3K |
| 72110 |
|
256 |
232 |
$3K |
| J7325 |
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg |
79 |
46 |
$3K |
| 82627 |
|
207 |
172 |
$3K |
| 95910 |
|
43 |
38 |
$3K |
| 94664 |
|
249 |
232 |
$3K |
| 78582 |
|
17 |
12 |
$3K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
1,258 |
1,083 |
$3K |
| 29075 |
|
75 |
53 |
$3K |
| 84207 |
|
159 |
144 |
$3K |
| J1726 |
Injection, hydroxyprogesterone caproate, (makena), 10 mg |
125 |
52 |
$3K |
| 00145 |
|
40 |
37 |
$3K |
| 86335 |
|
203 |
161 |
$3K |
| 80183 |
|
207 |
188 |
$3K |
| 52310 |
|
12 |
12 |
$3K |
| 81511 |
|
16 |
15 |
$3K |
| 86381 |
|
249 |
219 |
$3K |
| 92060 |
|
616 |
550 |
$3K |
| 85347 |
|
223 |
193 |
$2K |
| 36901 |
|
19 |
17 |
$2K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
17,203 |
14,922 |
$2K |
| 76514 |
|
402 |
369 |
$2K |
| L3908 |
Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf |
1,040 |
941 |
$2K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
3,795 |
3,269 |
$2K |
| Q5121 |
Injection, infliximab-axxq, biosimilar, (avsola), 10 mg |
14 |
12 |
$2K |
| 72193 |
|
33 |
28 |
$2K |
| 88304 |
|
2,414 |
2,143 |
$2K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
101 |
76 |
$2K |
| 92526 |
|
180 |
65 |
$2K |
| 36556 |
|
18 |
14 |
$2K |
| 0054A |
|
201 |
163 |
$2K |
| 90750 |
|
307 |
271 |
$2K |
| 86709 |
|
218 |
198 |
$2K |
| 36590 |
|
13 |
12 |
$2K |
| Q9956 |
Injection, octafluoropropane microspheres, per ml |
6,461 |
5,746 |
$2K |
| 62368 |
|
17 |
13 |
$2K |
| 91122 |
|
58 |
51 |
$2K |
| 85384 |
|
334 |
234 |
$2K |
| 84166 |
|
223 |
192 |
$2K |
| J2785 |
Injection, regadenoson, 0.1 mg |
3,528 |
3,126 |
$2K |
| 84080 |
|
314 |
274 |
$2K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
449 |
220 |
$2K |
| 87046 |
|
419 |
343 |
$2K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
16 |
14 |
$2K |
| 86308 |
|
197 |
181 |
$2K |
| 86015 |
|
261 |
233 |
$2K |
| 29515 |
|
69 |
62 |
$2K |
| 36416 |
|
18,072 |
10,355 |
$2K |
| 81206 |
|
19 |
13 |
$2K |
| 92604 |
|
129 |
105 |
$2K |
| 69210 |
|
222 |
196 |
$2K |
| 95913 |
|
133 |
129 |
$2K |
| C1769 |
Guide wire |
6,696 |
5,434 |
$2K |
| 93986 |
|
230 |
201 |
$2K |
| 82800 |
|
219 |
194 |
$2K |
| 29125 |
|
187 |
170 |
$2K |
| 84300 |
|
441 |
374 |
$2K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
46,020 |
34,347 |
$2K |
| 87147 |
|
350 |
309 |
$2K |
| 87486 |
|
77 |
58 |
$2K |
| C8924 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study |
18 |
12 |
$2K |
| 84446 |
|
197 |
171 |
$2K |
| 80074 |
|
46 |
39 |
$2K |
| 77049 |
|
12 |
12 |
$1K |
| 86003 |
|
30 |
28 |
$1K |
| 97035 |
|
122 |
57 |
$1K |
| 81403 |
|
32 |
28 |
$1K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
29,855 |
13,189 |
$1K |
| 86256 |
|
93 |
76 |
$1K |
| 99195 |
|
114 |
85 |
$1K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
2,779 |
2,452 |
$1K |
| 97760 |
|
120 |
102 |
$1K |
| 87581 |
|
77 |
58 |
$1K |
| 73000 |
|
394 |
331 |
$1K |
| C9053 |
Injection, crizanlizumab-tmca, 1 mg |
19 |
12 |
$1K |
| 86593 |
|
387 |
345 |
$1K |
| 97803 |
|
21 |
14 |
$1K |
| 12013 |
|
17 |
14 |
$1K |
| 90620 |
|
48 |
40 |
$1K |
| 84590 |
|
173 |
151 |
$1K |
| 85613 |
|
135 |
102 |
$1K |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
2,461 |
1,207 |
$1K |
| 84270 |
|
70 |
59 |
$1K |
| 88313 |
|
3,644 |
1,545 |
$1K |
| 93246 |
|
35 |
32 |
$1K |
| 20550 |
|
14 |
13 |
$1K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
4,368 |
3,481 |
$1K |
| G0444 |
Annual depression screening, 5 to 15 minutes |
30 |
28 |
$1K |
| 85660 |
|
240 |
171 |
$1K |
| 99496 |
|
35 |
30 |
$1K |
| 90678 |
|
151 |
135 |
$1K |
| 36600 |
|
381 |
328 |
$1K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
26,050 |
17,759 |
$1K |
| 0004A |
|
106 |
88 |
$999.10 |
| 90746 |
|
82 |
67 |
$977.91 |
| 70487 |
|
14 |
12 |
$968.17 |
| 92591 |
|
66 |
56 |
$959.89 |
| 84075 |
|
211 |
178 |
$930.10 |
| 80156 |
|
27 |
26 |
$929.28 |
| 80186 |
|
119 |
91 |
$917.97 |
| 80169 |
|
89 |
52 |
$917.94 |
| 82390 |
|
114 |
101 |
$915.66 |
| 82553 |
|
189 |
129 |
$912.19 |
| J9171 |
Injection, docetaxel, 1 mg |
76 |
49 |
$904.54 |
| 87184 |
|
174 |
160 |
$879.32 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
191 |
161 |
$855.04 |
| 96411 |
|
2,300 |
1,481 |
$821.83 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
21,550 |
17,872 |
$803.85 |
| 93299 |
|
16 |
13 |
$793.09 |
| J9073 |
Injection, cyclophosphamide (dr. reddy's), 5 mg |
25 |
13 |
$768.06 |
| 84157 |
|
156 |
137 |
$765.07 |
| 86376 |
|
64 |
61 |
$757.28 |
| 86146 |
|
62 |
48 |
$754.78 |
| 80203 |
|
42 |
36 |
$740.54 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
57,680 |
40,740 |
$739.50 |
| 77091 |
|
111 |
103 |
$724.93 |
| 92025 |
|
284 |
257 |
$722.80 |
| 72082 |
|
12 |
12 |
$684.71 |
| 92285 |
|
77 |
75 |
$657.03 |
| 80195 |
|
50 |
24 |
$652.05 |
| 87427 |
|
68 |
60 |
$645.02 |
| 83835 |
|
35 |
25 |
$644.42 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
5,000 |
4,000 |
$641.66 |
| 17000 |
|
30 |
24 |
$639.88 |
| 87899 |
|
51 |
37 |
$638.04 |
| 73523 |
|
248 |
236 |
$612.59 |
| 0031A |
|
24 |
20 |
$606.33 |
| 88173 |
|
1,009 |
848 |
$582.10 |
| 88312 |
|
2,846 |
1,340 |
$531.19 |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
5,076 |
4,849 |
$530.65 |
| 85732 |
|
92 |
67 |
$529.08 |
| 84295 |
|
54 |
51 |
$506.53 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
17,222 |
12,099 |
$498.45 |
| 82945 |
|
60 |
54 |
$498.01 |
| 93280 |
|
185 |
167 |
$488.71 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
38,552 |
29,218 |
$483.66 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
4,728 |
3,598 |
$478.94 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
404 |
350 |
$473.05 |
| C9113 |
Injection, pantoprazole sodium, per vial |
3,033 |
1,477 |
$465.97 |
| J9395 |
Injection, fulvestrant, 25 mg |
35 |
24 |
$456.45 |
| 95992 |
|
23 |
12 |
$435.53 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
28,279 |
20,421 |
$433.64 |
| 92593 |
|
28 |
26 |
$430.57 |
| 74246 |
|
14 |
13 |
$428.64 |
| J1644 |
Injection, heparin sodium, per 1000 units |
14,861 |
7,066 |
$426.56 |
| 86618 |
|
17 |
13 |
$422.61 |
| G0296 |
Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making) |
93 |
82 |
$408.26 |
| 71100 |
|
199 |
184 |
$395.03 |
| 0052A |
|
12 |
12 |
$381.60 |
| 82164 |
|
45 |
38 |
$375.81 |
| 84480 |
|
36 |
28 |
$370.35 |
| 94150 |
|
1,253 |
776 |
$360.58 |
| 87076 |
|
40 |
26 |
$352.72 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
7,596 |
4,922 |
$351.23 |
| 94761 |
|
3,139 |
2,872 |
$348.61 |
| C1750 |
Catheter, hemodialysis/peritoneal, long-term |
63 |
50 |
$338.34 |
| 91200 |
|
124 |
108 |
$327.97 |
| 70250 |
|
70 |
67 |
$322.17 |
| 98960 |
|
79 |
50 |
$319.92 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
6,143 |
4,799 |
$313.62 |
| J2704 |
Injection, propofol, 10 mg |
19,272 |
15,709 |
$264.16 |
| Q0239 |
Injection, bamlanivimab-xxxx, 700 mg |
15 |
13 |
$261.86 |
| 97763 |
|
19 |
12 |
$253.35 |
| 0352U |
|
333 |
306 |
$252.10 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
32 |
15 |
$248.05 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
11,325 |
8,392 |
$245.77 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
2,751 |
2,293 |
$245.58 |
| 87209 |
|
14 |
13 |
$239.96 |
| 82436 |
|
80 |
64 |
$239.73 |
| 82247 |
|
98 |
75 |
$238.25 |
| 84478 |
|
61 |
40 |
$234.14 |
| J2790 |
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) |
13 |
12 |
$226.80 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
9,316 |
5,424 |
$224.43 |
| 86905 |
|
40 |
30 |
$218.04 |
| 82435 |
|
68 |
61 |
$216.84 |
| 93282 |
|
49 |
39 |
$215.92 |
| P9612 |
Catheterization for collection of specimen, single patient, all places of service |
1,123 |
1,009 |
$210.05 |
| 84133 |
|
80 |
64 |
$207.52 |
| 83993 |
|
15 |
13 |
$203.81 |
| J2060 |
Injection, lorazepam, 2 mg |
5,762 |
4,203 |
$195.27 |
| 85598 |
|
16 |
12 |
$189.52 |
| 85597 |
|
17 |
12 |
$188.59 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
4,445 |
2,783 |
$172.39 |
| 46600 |
|
218 |
185 |
$168.74 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
2,845 |
2,383 |
$167.36 |
| 84155 |
|
88 |
77 |
$164.12 |
| J0173 |
Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg |
835 |
479 |
$160.98 |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
173 |
146 |
$159.71 |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
1,113 |
944 |
$158.85 |
| C1766 |
Introducer/sheath, guiding, intracardiac electrophysiological, steerable, other than peel-away |
299 |
255 |
$157.95 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
13,786 |
10,016 |
$156.53 |
| 90734 |
|
13 |
13 |
$154.16 |
| 88311 |
|
1,186 |
842 |
$150.41 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
9,608 |
7,717 |
$140.37 |
| 90632 |
|
13 |
13 |
$135.59 |
| 82525 |
|
18 |
12 |
$130.14 |
| 96377 |
|
1,055 |
756 |
$126.30 |
| 87177 |
|
14 |
13 |
$124.71 |
| 85525 |
|
17 |
12 |
$124.13 |
| Q9954 |
Oral magnetic resonance contrast agent, per 100 ml |
567 |
523 |
$117.12 |
| J3480 |
Injection, potassium chloride, per 2 meq |
2,501 |
1,685 |
$109.88 |
| 72070 |
|
15 |
14 |
$107.47 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
2,214 |
1,754 |
$100.73 |
| 82009 |
|
17 |
16 |
$100.30 |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
49 |
38 |
$97.61 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
4,460 |
3,846 |
$90.43 |
| 86906 |
|
37 |
27 |
$89.13 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
3,520 |
2,665 |
$87.30 |
| 71101 |
|
62 |
55 |
$86.55 |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
2,905 |
1,871 |
$83.71 |
| L3933 |
Finger orthosis, without joints, may include soft interface, custom fabricated, includes fitting and adjustment |
83 |
64 |
$82.81 |
| Q0111 |
Wet mounts, including preparations of vaginal, cervical or skin specimens |
15 |
13 |
$77.47 |
| J1939 |
Injection, bumetanide, 0.5 mg |
129 |
86 |
$77.07 |
| 89060 |
|
14 |
12 |
$72.63 |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
1,666 |
804 |
$70.09 |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
613 |
282 |
$69.62 |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
100 |
88 |
$65.80 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
3,080 |
2,616 |
$65.12 |
| L0172 |
Cervical, collar, semi-rigid thermoplastic foam, two-piece, prefabricated, off-the-shelf |
59 |
48 |
$54.03 |
| 73070 |
|
76 |
68 |
$53.80 |
| 82340 |
|
12 |
12 |
$51.60 |
| 85048 |
|
47 |
38 |
$49.15 |
| 84540 |
|
15 |
13 |
$46.29 |
| 84520 |
|
16 |
14 |
$39.01 |
| J1940 |
Injection, furosemide, up to 20 mg |
3,005 |
1,838 |
$38.12 |
| 82952 |
|
12 |
12 |
$36.54 |
| V2632 |
Posterior chamber intraocular lens |
1,606 |
1,306 |
$35.07 |
| C1729 |
Catheter, drainage |
1,260 |
724 |
$34.96 |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
395 |
328 |
$30.26 |
| L3906 |
Wrist hand orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment |
15 |
14 |
$28.27 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
5,355 |
4,220 |
$27.62 |
| J9190 |
Injection, fluorouracil, 500 mg |
2,192 |
1,142 |
$27.54 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
46 |
39 |
$24.81 |
| 77417 |
|
623 |
375 |
$24.16 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
3,757 |
2,517 |
$22.57 |
| J0610 |
Injection, calcium gluconate (fresenius kabi), per 10 ml |
634 |
290 |
$22.10 |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
1,095 |
757 |
$19.81 |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
13 |
12 |
$18.18 |
| J9045 |
Injection, carboplatin, 50 mg |
2,231 |
1,329 |
$17.96 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
9,062 |
5,285 |
$17.89 |
| G0328 |
Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous |
169 |
161 |
$17.50 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
1,091 |
892 |
$16.55 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
2,816 |
2,221 |
$15.86 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
6,725 |
3,122 |
$15.67 |
| J0612 |
Injection, calcium gluconate, not otherwise specified, 10 mg |
360 |
168 |
$15.33 |
| J1805 |
Injection, esmolol hydrochloride, 10 mg |
409 |
346 |
$14.90 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
2,247 |
1,524 |
$14.45 |
| 72020 |
|
26 |
25 |
$14.42 |
| 77387 |
|
433 |
93 |
$12.08 |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
822 |
735 |
$10.64 |
| C1726 |
Catheter, balloon dilatation, non-vascular |
326 |
274 |
$9.88 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
12,150 |
9,099 |
$9.05 |
| J9267 |
Injection, paclitaxel, 1 mg |
1,440 |
604 |
$8.37 |
| Q9969 |
Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose |
341 |
308 |
$8.28 |
| 91312 |
|
375 |
305 |
$7.82 |
| J1790 |
Injection, droperidol, up to 5 mg |
3,071 |
2,599 |
$6.94 |
| J1630 |
Injection, haloperidol, up to 5 mg |
2,031 |
1,497 |
$6.29 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
894 |
775 |
$5.77 |
| C1760 |
Closure device, vascular (implantable/insertable) |
599 |
464 |
$3.70 |
| J3411 |
Injection, thiamine hcl, 100 mg |
1,465 |
911 |
$3.54 |
| J3473 |
Injection, hyaluronidase, recombinant, 1 usp unit |
150 |
116 |
$3.07 |
| A4648 |
Tissue marker, implantable, any type, each |
59 |
48 |
$3.03 |
| 86790 |
|
14 |
12 |
$2.87 |
| J1953 |
Injection, levetiracetam, 10 mg |
839 |
624 |
$1.51 |
| J0697 |
Injection, sterile cefuroxime sodium, per 750 mg |
1,003 |
799 |
$1.12 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
487 |
389 |
$0.99 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
332 |
292 |
$0.64 |
| J1836 |
Injection, metronidazole, 10 mg |
496 |
352 |
$0.30 |
| 91305 |
|
204 |
177 |
$0.14 |
| J0280 |
Injection, aminophyllin, up to 250 mg |
157 |
141 |
$0.07 |
| 91303 |
|
23 |
19 |
$0.02 |
| 88365 |
|
16 |
14 |
$0.00 |
| C1758 |
Catheter, ureteral |
663 |
573 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
2,558 |
2,207 |
$0.00 |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
152 |
137 |
$0.00 |
| C1788 |
Port, indwelling (implantable) |
442 |
392 |
$0.00 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
108 |
90 |
$0.00 |
| 73100 |
|
31 |
25 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
422 |
282 |
$0.00 |
| 73551 |
|
13 |
12 |
$0.00 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
458 |
339 |
$0.00 |
| J9999 |
Not otherwise classified, antineoplastic drugs |
329 |
159 |
$0.00 |
| 91300 |
|
761 |
657 |
$0.00 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
308 |
274 |
$0.00 |
| 88346 |
|
35 |
26 |
$0.00 |
| 88302 |
|
86 |
62 |
$0.00 |
| J0744 |
Injection, ciprofloxacin for intravenous infusion, 200 mg |
265 |
197 |
$0.00 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
231 |
208 |
$0.00 |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
502 |
198 |
$0.00 |
| C2625 |
Stent, non-coronary, temporary, with delivery system |
261 |
243 |
$0.00 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
110 |
90 |
$0.00 |
| 73010 |
|
25 |
24 |
$0.00 |
| 92081 |
|
17 |
13 |
$0.00 |
| G8990 |
Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals |
18 |
12 |
$0.00 |
| G8989 |
Self care functional limitation, discharge status, at discharge from therapy or to end reporting |
225 |
204 |
$0.00 |
| J0692 |
Injection, cefepime hydrochloride, 500 mg |
146 |
50 |
$0.00 |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
111 |
98 |
$0.00 |
| 77012 |
|
64 |
51 |
$0.00 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
109 |
98 |
$0.00 |
| 0441U |
|
50 |
47 |
$0.00 |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
75 |
48 |
$0.00 |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
52 |
24 |
$0.00 |
| C1752 |
Catheter, hemodialysis/peritoneal, short-term |
16 |
13 |
$0.00 |
| L0140 |
Cervical, semi-rigid, adjustable (plastic collar) |
12 |
12 |
$0.00 |
| 0100U |
|
24 |
24 |
$0.00 |
| J1071 |
Injection, testosterone cypionate, 1 mg |
17 |
13 |
$0.00 |
| J2310 |
Injection, naloxone hydrochloride, per 1 mg |
15 |
12 |
$0.00 |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
24 |
12 |
$0.00 |
| A9270 |
Non-covered item or service |
492 |
459 |
$0.00 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
359 |
289 |
$0.00 |
| G8981 |
Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals |
109 |
89 |
$0.00 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
472 |
384 |
$0.00 |
| J0706 |
Injection, caffeine citrate, 5 mg |
14 |
13 |
$0.00 |
| A9555 |
Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries |
116 |
103 |
$0.00 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
465 |
402 |
$0.00 |
| C1830 |
Powered bone marrow biopsy needle |
53 |
38 |
$0.00 |
| J3360 |
Injection, diazepam, up to 5 mg |
134 |
108 |
$0.00 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
494 |
296 |
$0.00 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
74 |
38 |
$0.00 |
| J1920 |
Injection, labetalol hydrochloride, 5 mg |
531 |
376 |
$0.00 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
823 |
363 |
$0.00 |
| G9172 |
Voice functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
14 |
12 |
$0.00 |
| C9290 |
Injection, bupivacaine liposome, 1 mg |
145 |
131 |
$0.00 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
110 |
57 |
$0.00 |
| L3808 |
Wrist hand finger orthosis, rigid without joints, may include soft interface material; straps, custom fabricated, includes fitting and adjustment |
66 |
59 |
$0.00 |
| 76377 |
|
59 |
48 |
$0.00 |
| C1781 |
Mesh (implantable) |
49 |
41 |
$0.00 |
| G8983 |
Changing & maintaining body position functional limitation, discharge status, at discharge from therapy or to end reporting |
31 |
25 |
$0.00 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
14 |
14 |
$0.00 |
| G8982 |
Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
144 |
123 |
$0.00 |
| G8991 |
Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
19 |
13 |
$0.00 |
| J8501 |
Aprepitant, oral, 5 mg |
30 |
26 |
$0.00 |
| G8986 |
Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting |
13 |
13 |
$0.00 |
| A9540 |
Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries |
47 |
41 |
$0.00 |
| G8998 |
Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting |
42 |
35 |
$0.00 |
| 88350 |
|
35 |
26 |
$0.00 |
| J7507 |
Tacrolimus, immediate release, oral, 1 mg |
46 |
14 |
$0.00 |
| C1889 |
Implantable/insertable device, not otherwise classified |
29 |
27 |
$0.00 |
| G0472 |
Hepatitis c antibody screening, for individual at high risk and other covered indication(s) |
14 |
14 |
$0.00 |
| J0500 |
Injection, dicyclomine hcl, up to 20 mg |
32 |
29 |
$0.00 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
35 |
34 |
$0.00 |
| 73600 |
|
19 |
12 |
$0.00 |
| L4350 |
Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf |
43 |
41 |
$0.00 |
| 88300 |
|
12 |
12 |
$0.00 |
| J2471 |
Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg |
26 |
12 |
$0.00 |
| C1893 |
Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away |
21 |
19 |
$0.00 |